Faculty of Medicine, Minia University, Minia, Egypt.
Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Dermatol Ther. 2022 Dec;35(12):e15900. doi: 10.1111/dth.15900. Epub 2022 Oct 17.
Despite the significant reduction of both morbidity and mortality after the introduction of many vaccines against COVID-19, recent reports indicated a worsening skin conditions in particular patients with psoriasis. We extracted the data of 51 patients from 19 papers. The mean age was 56.9 (SD = 16.2) years, with a male prevalence 45%. Of the 51 cases, vaccine types at which psoriasis flare occurred were as the following: Pfizer vaccine (30), AstraZeneca (9), Moderna (8), Coronavac (2) Covishield (1), and Covaxin (1). Exacerbation was common in the second dose of Pfizer, AstraZeneca, Moderna, and Covishield vaccines. Moreover, the onset of psoriasis exacerbation was shorter after the second dose of Pfizer (mean = 12.8 [SD = 15.2]) and AstraZeneca (mean = 7.4 [SD = 3.6]) rather than the first dose of both vaccines, respectively (mean = 19.2 [SD = 21.3]) and (mean = 18.5 [SD = 10.7]).
尽管 COVID-19 疫苗的广泛接种显著降低了发病率和死亡率，但最近的报告表明，特定的银屑病患者的皮肤状况恶化。我们从 19 篇论文中提取了 51 名患者的数据。平均年龄为 56.9 岁（标准差=16.2），男性患病率为 45%。在这 51 例病例中，出现银屑病发作的疫苗类型如下：辉瑞疫苗（30 例）、阿斯利康（9 例）、莫德纳（8 例）、科兴（2 例）、Covishield（1 例）和 Covaxin（1 例）。在辉瑞、阿斯利康和莫德纳疫苗的第二剂中，加重的情况更为常见。此外，与两疫苗的第一剂相比，第二剂 Pfizer（平均=12.8 [SD=15.2]）和 AstraZeneca（平均=7.4 [SD=3.6]）的银屑病发作起始时间更短。
